Korean Biotech Files US IND for RNAi Drug Targeting MyD88 Amplifier in Geographic Atrophy

0 points · first seen 19h ago · 1 outlet · 0 comments

Geographic atrophy treatment has a new entrant: OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence. OLX301A now enters the FDA 30-day review window; enrollment in a 64-patient Phase 2a trial in the US, Australia, and New Zealand begins if cleared. — Tech Times

save

· share to X · Bluesky · copy link